Skip to main content
CONCORDBIO · Health Care · 2026-08-07

Concord Biotech Ltd

4.5WatchEven +1.3Stage 2 · wk 2In scan: Prop Scan · Breakout WatchMARKET: BULL TOPPING · 2026-08-07
₹1,365
-0.71% today
₹14,280 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.

Visit company website →
P/E (TTM)
37.0
Forward 29.1
Earnings Growth (YoY)
-16.3%
Revenue +13.7%
Dividend Yield
0.94%
P/B 6.3
vs 52W High
-22.3%
₹1,014.8 lo₹1,756.4 hi
22.3% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 2
1w13w26w
Week 2 — fresh breakout, verify structure
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
7.9%
200 DMA: ₹1,265.3 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.19x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 gently rising · +2.8% vs MA50 +6.1%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #76 of 79 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Ranks #50 of 53 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-08-18 → 2026-08-07
S? 43w
S2 32w
S4 42w
2023-08-182026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 43w → S3 3w → S2 32w → S3 5w → S4 11w → S1 10w → S4 42w → S1 7w → S2 1w current
Total tracked: 155 weeks across 9 stage runs.
1M
+4.6%
3M
+16.3%
6M
+23.1%
YTD
+2.2%
1Y
-24.7%
Scan Membership
Prop Scan
Latest: 2026-08-07
Breakout Watch
Latest: 2026-07-31
8 appearances in last 60 days. First seen: 2024-07-08.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 2 · Vol x
2026-08-06S2
Wk 1 · Vol x
2026-08-05S2
Wk 1 · Vol x
2026-08-04S2
Wk 1 · Vol x
2026-08-03S2
Wk 1 · Vol x
2026-07-31S21→2
Wk 1 · Vol x
2026-07-30S1
Wk 7 · Vol x
2026-07-29S1
Wk 7 · Vol x
2026-07-28S1
Wk 7 · Vol x
2026-07-27S1
Wk 7 · Vol x
2026-07-24S1
Wk 6 · Vol x
2026-07-23S1
Wk 6 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹1,299.1
200 DMA
₹1,265.3
52W High
₹1,756.4
52W Low
₹1,014.8
5D Low
₹1,365
Resistance levels (recent highs)
20d High
₹1,420.8
60d High
₹1,420.8
120d High
₹1,420.8
250d High
₹1,756.4
Next resistance
+4.1%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.